Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study
Sponsor: Association of Urologic Oncology (AUO)
Listed as NCT00146276, this PHASE3 trial focuses on Bladder Cancer and Carcinoma, Transitional Cell and remains ongoing. Sponsored by Association of Urologic Oncology (AUO), it has been updated 7 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
▶ Show 2 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2018 [monthly]
Unknown Status PHASE3
First recorded
Jul 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Association of Urologic Oncology (AUO)
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .